About Us

Teikoku Pharma USA located in San Jose California and headquartered in Kagawa Japan, is a pharmaceutical company focused on the research and development of treatments for CNS, Pain Management and Oncology.  Founded in 1997, the company successfully developed Lidocaine 5% patch worldwide under Lidoderm®, Lidotop® and  Versatis® brands.  To date, 2 billion Lidocaine 5% patches have been distributed in 59 countries.  TPU recently also received NDA approval for Non-alcohol Docetaxel injection currently available in the US.

Latest News and Events

August 22, 2017

Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non Opioid Pain Management Patch in Bunionectomy Surgery
SAN JOSE, Calif., Aug. 22, 2017—Teikoku Pharma USA, Inc. (Teikoku Pharma) today announced positive topline results from its Phase 2 proof of concept study of TPU-006, a 3-day dexmedetomidine transdermal patch, a novel drug delivery system with a non-opioid active moiety for the management of post-surgical pain. The preliminary results demonstrate that the patch provides effective pain control across several parameters and produced no unexpected safety events in a postoperative setting.

Read more | View All


Teikoku is building a robust pipeline of drug candidates which may expand the reach and benefit of existing therapeutics.   

Learn more about our pipeline.


Teikoku USA has two FDA and one EMEA approved products in the market.
Learn more about our approved products.


We employ our Hydrohesive, Matrix and other drug delivery technologies to expand our product pipeline.
Learn More About Our Technologies.